Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Chemotherapy for bladder cancer in patients with impaired renal function

Nature Reviews Urology volume 9, pages 52–57 (2012)Cite this article

Subjects

Abstract

Carcinoma of the bladder is a common, chemosensitive malignancy. The value of chemotherapy for transitional cell carcinoma (the commonest malignant bladder histology in the developed world) has been demonstrated in both the palliative and the neoadjuvant settings, with survival benefits in both scenarios being achieved with cisplatin-based regimens. Conventional drug treatment is, therefore, dependent on adequate renal function, but renal impairment is a common confounding factor in patients with bladder cancer, due in part to obstruction of the urinary tract and in part to comorbidity in an elderly population. A recent consensus statement deems patients with impaired renal function unsuitable for cisplatin treatment, but the limited available evidence does not support the exclusion of cisplatin in patients with moderate renal impairment. The literature on which to base alternative, non-cisplatin-based chemotherapy is inadequate, but the perception that carboplatin-based combinations are inferior to cisplatin-based combinations is probably incorrect. Trials are needed to specifically examine chemotherapy in patients with bladder cancer and renal impairment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bladder cancer—UK incidence statistics. Cancer Research UK [online], (2011).

  2. Dash, A. et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506–513 (2006).

    Article  CAS  PubMed  Google Scholar 

  3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1–S266 (2002).

  4. Galsky, M. D. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 12, 211–214 (2011).

    Article  PubMed  Google Scholar 

  5. Raj, G. V., Iasonos, A., Herr, H. & Donat, S. M. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J. Clin. Oncol. 24, 3095–3100 (2006).

    Article  CAS  PubMed  Google Scholar 

  6. Merrin, C. Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J. Urol. 119, 493–495 (1978).

    Article  CAS  PubMed  Google Scholar 

  7. Soloway, M. S. Cis-diamminedichloroplatinum II in advanced urothelial cancer. J. Urol. 120, 716–719 (1978).

    Article  CAS  PubMed  Google Scholar 

  8. Prestayko, A. W., Luft, F. C., Einhorn, L. & Crooke, S. T. Cisplatin pharmacokinetics in a patient with renal dysfunction. Med. Pediatr. Oncol. 5, 183–188 (1978).

    Article  CAS  PubMed  Google Scholar 

  9. Ribrag, V. et al. Test dose-guided administration of cisplatin in an anephric patient: a case report. Ann. Oncol. 4, 679–682 (1993).

    Article  CAS  PubMed  Google Scholar 

  10. Haim, N. et al. Estimation of creatinine clearance without 24-hour urine collection—a useful guide during cisplatin therapy. Acta Oncol. 32, 409–412 (1993).

    Article  CAS  PubMed  Google Scholar 

  11. Mead, G. M. et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer 78, 1067–1075 (1998).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. von der Maase, H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 17, 3068–3077 (2000).

    Article  Google Scholar 

  13. Carles, J. et al. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function. Clin. Transl. Oncol. 8, 755–757 (2006).

    Article  CAS  PubMed  Google Scholar 

  14. Hussain, S. A. et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br. J. Cancer 91, 844–849 (2004).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Petrioli, R. et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77, 344–351 (1996).

    Article  CAS  PubMed  Google Scholar 

  16. Bellmunt, J. et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966–1972 (1997).

    Article  CAS  PubMed  Google Scholar 

  17. Bellmunt, J., de Wit, R., Albanell, J. & Baselga, J. A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. Eur. J. Cancer 37, 2212–2215 (2001).

    Article  CAS  PubMed  Google Scholar 

  18. Carles, J. et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59, 24–27 (2000).

    Article  CAS  PubMed  Google Scholar 

  19. Linardou, H. et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64, 479–484 (2004).

    Article  PubMed  Google Scholar 

  20. Nogué-Aliguer, M. et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract. Cancer 97, 2180–2186 (2003).

    Article  PubMed  Google Scholar 

  21. Shannon, C. et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann. Oncol. 12, 947–952 (2001).

    Article  CAS  PubMed  Google Scholar 

  22. De Santis, M. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J. Clin. Oncol. 27, 5634–5639 (2009).

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Dogliotti, L. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134–141 (2007).

    Article  CAS  PubMed  Google Scholar 

  24. Galsky, M. D. et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr156

  25. Dreicer, R. et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639–1645 (2004).

    Article  CAS  PubMed  Google Scholar 

  26. Calvert, A. H. & Egorin, M. J. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur. J. Cancer 38, 11–16 (2002).

    Article  CAS  PubMed  Google Scholar 

  27. Roth, B. et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 12, 2264–2270 (1994).

    Article  CAS  PubMed  Google Scholar 

  28. Dimopoulos, M. A. et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 52, 56–60 (1998).

    Article  CAS  PubMed  Google Scholar 

  29. Vaughn, D. J. et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 16, 255–260 (1998).

    Article  CAS  PubMed  Google Scholar 

  30. Friedland, D. M., Dakhil, S., Hollen, C., Gregurich, M. A. & Asmar, L. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Cancer Invest. 22, 374–382 (2004).

    Article  CAS  PubMed  Google Scholar 

  31. Johannsen, M. et al. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Eur. Urol. 48, 246–251 (2005).

    Article  CAS  PubMed  Google Scholar 

  32. Kouno, T. et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur. Urol. 52, 1115–1122 (2007).

    Article  CAS  PubMed  Google Scholar 

  33. Fechner, G. et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract. 60, 27–31 (2006).

    Article  CAS  PubMed  Google Scholar 

  34. Matsumoto, K. et al. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int. J. Urol. 14, 1000–1004 (2007).

    Article  CAS  PubMed  Google Scholar 

  35. Suyama, T. et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J. Clin. Oncol. 39, 244–250 (2009).

    Article  PubMed  Google Scholar 

  36. Hussain, M., Vaishampayan, U., Du, W., Redman, B. & Smith, D. C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19, 2527–2533 (2001).

    Article  CAS  PubMed  Google Scholar 

  37. Pectasides, D. et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann. Oncol. 13, 243–250 (2002).

    Article  CAS  PubMed  Google Scholar 

  38. Galsky, M. D. et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109, 549–555 (2007).

    Article  CAS  PubMed  Google Scholar 

  39. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202–205 (2005).

  40. Winquist, E. et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171, 561–569 (2004).

    Article  CAS  PubMed  Google Scholar 

  41. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48, 189–199 (2005).

  42. Ghoneim, M. A., el-Mekresh, M. M., el-Baz, M. A., el-Attar, I. A. & Ashamallah, A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol. 158, 393–399 (1997).

    Article  CAS  PubMed  Google Scholar 

  43. Galsky, M. D. et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 69, 255–259 (2007).

    Article  PubMed  Google Scholar 

  44. Swanson, D. A., Liles, A. & Zagars, G. K. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J. Urol. 143, 37–40 (1990).

    Article  CAS  PubMed  Google Scholar 

  45. Serretta, V., Pomara, G., Piazza, F. & Gange, E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur. Urol. 37, 85–89 (2000).

    Article  CAS  PubMed  Google Scholar 

  46. Richie, J. P., Waisman, J., Skinner, D. G. & Dretler, S. P. Squamous carcinoma of the bladder: treatment by radical cystectomy. J. Urol. 115, 670–672 (1976).

    Article  CAS  PubMed  Google Scholar 

  47. Rundle, J. S. et al. Squamous cell carcinoma of bladder. A review of 114 patients. Br. J. Urol. 54, 522–526 (1982).

    Article  CAS  PubMed  Google Scholar 

  48. Choong, N., Quevedo, J. & Kaur, J. Small cell carcinoma of the urinary bladder. Cancer 103, 1172–1178 (2005).

    Article  PubMed  Google Scholar 

  49. Kaya, A. O. et al. Primary pure small cell carcinoma of the urinary bladder that responded to carboplatin plus etoposide: a case report and review of the literature. J. BUON 14, 703–706 (2009).

    CAS  PubMed  Google Scholar 

  50. Bex, A. et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 65, 295–299 (2005).

    Article  PubMed  Google Scholar 

  51. Mukesh, M., Cook, N., Hollingdale, A. E., Ainsworth, N. L. & Russell, S. G. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int. 103, 747–752 (2009).

    Article  CAS  PubMed  Google Scholar 

  52. Tran, B. & McKendrick, J. Metastatic urachal cancer responding to FOLFOX chemotherapy. Can. J. Urol. 17, 5120–5123 (2010).

    PubMed  Google Scholar 

  53. Mohile, S. G., Schleicher, L. & Petrylak, D. P. Treatment of metastatic urachal carcinoma in an elderly woman. Nat. Clin. Pract. Oncol. 5, 55–58 (2008).

    Article  PubMed  Google Scholar 

  54. Logothetis, C. J., Samuels, M. L. & Ogden, S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology 26, 252–255 (1985).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Studies & Molecular Medicine, University of Leicester, 2nd Floor, Osborne Building, Leicester Royal Infirmary, Leicester, LE1 5WW, UK

    Steve Nicholson

Authors
  1. Steve Nicholson
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nicholson, S. Chemotherapy for bladder cancer in patients with impaired renal function. Nat Rev Urol 9, 52–57 (2012). https://doi.org/10.1038/nrurol.2011.176

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2011.176

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing